Research programme: autoimmune and inflammatory disease therapies - CytoGenix

Drug Profile

Research programme: autoimmune and inflammatory disease therapies - CytoGenix

Alternative Names: CY-303; Lung inflammation therapy research programme - CytoGenix; Research programme: lung inflammation therapy - CytoGenix; Topical skin inflammation therapy - CytoGenix

Latest Information Update: 11 Dec 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CytoGenix
  • Class
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Inflammation; Psoriasis

Most Recent Events

  • 13 Nov 2013 BioZone Pharmaceuticals enters into an agreement to sell its operating assets, including QuSomes™, to MusclePharm
  • 22 Oct 2003 This programme is available for licensing (
  • 15 Aug 2003 Preclinical trials in Psoriasis in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top